Welcome to our dedicated page for Cellectis S.A. American Depositary Shares news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis S.A. American Depositary Shares stock.
Cellectis S.A. (symbol: CLLS) is a clinical-stage biopharmaceutical company that specializes in developing cutting-edge cancer immunotherapies using gene-edited T-cells, known as UCART. With over 18 years of experience in gene editing, Cellectis leverages its proprietary TALEN® technology and PulseAgile electroporation system to harness the power of the immune system to combat cancer.
Cellectis is dedicated to creating innovative products in the fields of immuno-oncology and beyond. Its portfolio includes allogeneic Chimeric Antigen Receptor T-cells (CAR-T) product candidates and gene-edited hematopoietic stem and progenitor cells (HSPC) for various therapeutic applications.
Recent achievements include advancements in gene correction and gene insertion technologies, presented at esteemed scientific conferences. For instance, the company has introduced a novel method for circularizing non-viral single-strand DNA templates, enhancing gene editing outcomes in HSPCs. Cellectis is also collaborating with renowned pharmaceutical companies like AstraZeneca, further expanding its pipeline of allogeneic CAR T-cell therapies.
Financially, Cellectis is listed on both the NASDAQ (ticker: CLLS) and the NYSE Alternext (ticker: ALCLS) markets. The company's ongoing projects and research efforts are supported by robust investment and partnership agreements, showcasing its commitment to improving health outcomes through innovative biotechnological solutions.
For more information, visit the company's website at www.cellectis.com.
Cellectis, a clinical-stage biotechnology company, presented groundbreaking research at the American Society of Cell and Gene Therapy Annual Meeting on May 16, 2022. The data focuses on a novel universal CAR T-cell, ΔTRACCARΔB2MHLAE, designed with immune-evasive properties via TALEN® gene editing. This IMMUNO-evasive CAR T-cell effectively evades attacks from NK cells and alloresponsive T-cells, demonstrating prolonged antitumor activity in vitro and in vivo. The findings indicate promising avenues for allogeneic CAR T-cell therapies.
Cellectis, a clinical-stage biotechnology company, reported significant progress in Q1 2022, with a cash position of $142 million expected to fund operations into early 2024. The company presented robust preclinical data for UCART20x22 and published key validations for UCART123 in Nature Communications. Cellectis received a $20 million convertible note from Cytovia Therapeutics as part of their collaboration. However, Q1 revenues plummeted to $4 million from $28 million, leading to a net loss of $32 million. The company maintains focus on advancing its CAR T platform and seeks to file an IND for UCART20x22.
Cellectis, a clinical-stage biotechnology company, continues to develop gene-editing therapies for cancer and blood disorders. As of April 30, 2022, Cellectis reported a total of 45,510,810 shares in capital and 51,103,431 voting rights. The company focuses on allogeneic CAR-T therapies and novel approaches in gene editing using TALEN® technology. Cellectis aims to provide lifesaving treatments for conditions like acute myeloid leukemia and multiple myeloma while maintaining a commitment to address unmet medical needs.
Cellectis, a clinical-stage biotechnology company specializing in gene-editing, has announced its financial results for Q1 2022 will be released on May 12, 2022. A conference call is scheduled for May 13, 2022, at 8:00 AM EDT to discuss these results and provide a business update. Cellectis focuses on developing innovative CAR-T immunotherapies using its TALEN® gene editing technology and PulseAgile electroporation system. The company operates in the U.S. and France and is listed on Nasdaq under the ticker CLLS.
Cellectis S.A. (NASDAQ: CLLS) has announced Calyxt, its subsidiary, reported first-quarter 2022 results. Calyxt generated nominal revenue due to the discontinuation of its soybean product line, down from $4.4 million in Q1 2021. Operating expenses fell to $6.1 million, resulting in a net loss of $5.6 million compared to $10.0 million in the previous year. Calyxt's advancements include evaluating 28 customer-identified molecules and enhancing its BioFactory production capabilities, as well as raising $10 million from a stock offering, which will support technology scaling and customer engagement.
Cellectis has published promising preclinical data regarding its gene-edited CAR T-cell therapy candidate, UCART123, targeting acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). Results demonstrate that UCART123 effectively eliminates AML cells with minimal impact on normal hematopoietic progenitor cells, supporting its clinical evaluation in the ongoing Phase 1 AMELI-01 trial. The therapy has shown potent anti-BPDCN activity and improved overall survival in patient-derived models, enhancing its potential as a treatment option for patients with unmet medical needs.
Cellectis has announced a collaboration with Cytovia Therapeutics, which has entered into a business combination agreement with Isleworth Healthcare Acquisition Corp. The deal, expected to list the combined company under the ticker INKC on NASDAQ, includes a $20 million convertible note as part of Cellectis' upfront consideration. The agreement stems from their ongoing partnership to develop gene-edited Natural Killer cells using Cellectis' TALEN® technology. Financial terms also encompass potential milestone payments totaling up to $805 million, alongside royalty payments on net sales.
Cellectis announced promising preclinical data for its allogeneic dual CAR T-cell candidate, UCART20x22, targeting relapsed or refractory Non-Hodgkin Lymphoma (r/r NHL). The data demonstrate significant in vitro and in vivo anti-tumor activity, potentially overcoming common resistance mechanisms. UCART20x22 aims to simplify treatment by being fully developed and manufactured in-house, with an Investigational New Drug application expected this year. This marks a pivotal step in Cellectis’ strategy as it transitions to a comprehensive cell and gene therapy platform.
Cellectis, a clinical-stage biotechnology company, reported its share structure as of March 31, 2022. The company has a total of 45,490,810 shares in capital and 51,083,431 voting rights. Cellectis utilizes its gene-editing platform to develop therapies for various cancers and genetic disorders. Its UCART product candidates target diseases like acute myeloid leukemia and multiple myeloma. The company's commitment is to provide innovative therapies using its proprietary technologies, including TALEN® and PulseAgile.
Cellectis, a clinical-stage biotechnology company focused on gene editing, announced its participation in two important healthcare conferences: the Oppenheimer & Co. Annual Healthcare Conference on March 16, 2022, at 4:00 PM EST, and the Barclays Global Healthcare Conference on March 17, 2022, at 9:30 AM EST. Both events will feature live webcasts available on their investor website. Cellectis aims to advance its innovative CAR-T therapies, targeting diseases like leukemia and multiple myeloma, utilizing its proprietary gene-editing technology TALEN®.
FAQ
What is the current stock price of Cellectis S.A. American Depositary Shares (CLLS)?
What is the market cap of Cellectis S.A. American Depositary Shares (CLLS)?
What does Cellectis S.A. specialize in?
What proprietary technologies does Cellectis use?
What are UCART cells?
What recent advancements has Cellectis made?
Which companies has Cellectis partnered with?
On which stock markets is Cellectis listed?
What are HSPCs?
How long has Cellectis been in the gene editing field?
Where can I find more information about Cellectis?